Correlation Between Expression Of PLOD2 And Acquired Resistance Of The First Generation Of EGFR-TKI In Advanced Lung Adenocarcinoma

BackgroundLung cancer is still one of the most common malignant tumors in the world.Its incidence rate and mortality rate increase year by year.It seriously threatens human health.Molecular targeted therapy,such as Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI),has made breakthrough progress in the treatment of lung cancer.Which brings good news for lung cancer patients.However,drug resistance is inevitable.Procollagen-lysine,2-oxoglutarate5-dioxygenase2(PLOD2)is an important collagen modified enzyme.Which is closely related to the development of systemic multi-system tumor,it remains to be explored whether the expression of PLOD2 is related to the resistance of lung cancer patients to the first generation of EGFR-TKI.ObjectiveObjective to investigate the relationship between the expression of PLOD2 and clinicopathological features of lung adenocarcinoma and the acquired resistance of the first generation of EGFR-TKI.Methods60 patients with advanced lung adenocarcinoma who received the first generation of EGFR-TKI treatment in the First Affiliated Hospital of Xinxiang Medical College from October 2018 to March 2020 were selected as the research objects.The expression of PLOD2 in pathological sections of patients before and after drug resistance was detected by immunohistochemical method,and the relationship between the expression of PLOD2 and clinicopathological characteristics and EGFR-TKI acquired resistance was analyzed department.Results1.In 60 cases of lung adenocarcinoma patients,46 cases had disease progression during the course of medication,and tissue samples were obtained after drug resistance.Through immunohistochemical detection,it was found that the expression level of PLOD2 in the pathological tissues of patients after drug resistance was higher than that before medication,and the difference was statistically significant(P ?0.05).2.In 60 cases of lung adenocarcinoma patients,46 cases had disease progression during the course of medication,and obtained the tissue samples after drug resistance.Through immunohistochemical detection,it was found that the expression level of PLOD2 in the pathological tissues of patients after drug resistance was higher than that before medication,and the difference was statistically significant(P ? 0.05).3.Kaplan Meier univariate survival analysis showed that the expression level of PLOD2,lymph node metastasis and distant metastasis were correlated with the progression free survival of patients with lung adenocarcinoma,and the difference was statistically significant(P ?0.05).The progression free survival of patients with high expression of PLOD2 was 7.3 months,the progression free survival of patients with low expression of PLOD2 was 11.7 months;The progression free survival(PFS)of high expression of PLOD2 was significantly lower than that of low expression of PLOD2.4.Multivariate analysis of Cox proportional hazards model showed that the expression of PLOD2 was correlated with progression free survival(Exp(β)value of PLOD2 was 0.337,95% CI was 0.169-0.672,P ?0.05).5.Analyze the relationship between the expression of PLOD2 and the clinicopathological parameters,including gender,age,drug resistance,T790 M mutation.The results showed that there was no correlation between the expression of PLOD2 and the above pathological parameters,and the difference was not statistically significant.Conclusion1.The expression level of PLOD2 is correlated with distant metastasis and progression free survival of lung adenocarcinoma,indicating that PLOD2 can promote the occurrence and development of lung adenocarcinoma.2.PLOD2 may be a marker of the first generation of EGFR-TKI acquired resistance in lung adenocarcinoma,and its high expression may be an important reason for the first generation of EGFR-TKI acquired resistance.